Bortezomib liquid Spirig HC
Bortezomib liquid Spirig HC is a generic from Spirig HealthCare AG and is listed on the FOPH Specialities List. Basic health insurance reimburses it within the authorised indication. The public price ranges from CHF 421.85 to CHF 713.75 depending on the pack; the co-payment is 10 per cent.
Core data
- Authorisation holder
- Spirig HealthCare AG
- ATC code
- L01XG01
- IT group
- 07.16.10 Cytostatica
- Active substances
- Bortezomibum
- Preparation type
- Generic
- On the SL since
- 01/02/2020
- Last price change
- 01/02/2024
- Co-payment
- 10%
Prices per pack
The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.
| Dosage form | Pack size | Ex-factory price | Public price | Valid from | Cat. | GTIN |
|---|---|---|---|---|---|---|
| Inj Lös 3.5 mg/1.4ml | Durchstf 1 Stk | CHF 372.78 | CHF 421.85 | 01/02/2020 | A | 7680674210016 |
| Inj Lös 7 mg/2.8ml | Durchstf 1 Stk | CHF 641.18 | CHF 713.75 | 01/10/2023 | A | 7680674210023 |
Limitation
This preparation is reimbursed only under the conditions below. The text is the binding FOPH wording; outside those conditions basic insurance does not pay.
The FOPH publishes limitation texts in German, French and Italian only. The German wording is reproduced verbatim below.
Für die Behandlung mit BORTEZOMIB LIQUID SPIRIG HC ist keine neue Kostengutsprache nötig, wenn in derselben Indikation bereits eine Kostengutsprache für das Originalpräparat oder ein anderes Generikum besteht.
Zur Induktionsbehandlung in Kombination mit Standardchemotherapie vor Stammzelltransplantation bei erwachsenen Patienten mit multiplem Myelom.
In Kombination mit Melphalan und Prednison bei bisher unbehandelten Patienten mit multiplem Myelom.
Zur Behandlung von Patienten mit rezidivierendem/refraktärem multiplem Myelom, welche mindestens eine vorhergehende Therapie erhielten.
Die Therapien bedürfen der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.
More preparations in this group
FAQ
Is Bortezomib liquid Spirig HC covered by Swiss health insurance?
Yes, but only under conditions. Bortezomib liquid Spirig HC is on the Specialities List with a limitation: basic insurance reimburses it only when the conditions in the limitation text are met, in some cases only after the insurer has granted cost approval.
What does Bortezomib liquid Spirig HC cost in Switzerland?
The public price is the maximum price set by the FOPH and for Bortezomib liquid Spirig HC ranges from CHF 421.85 to CHF 713.75 per pack. The ex-factory price ranges from CHF 372.78 to CHF 641.18. Pharmacies may not charge more, but may charge less.
Market access
Do you need your product on the Specialities List?
Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.
- Independent directory
- Official FOPH data
- Website in eight languages